Abstract | INTRODUCTION: METHODS: Potential pharmacokinetic interactions between 20 mg dapagliflozin, 40 mg simvastatin, or 320 mg valsartan were assessed in an open-label, randomized, five-period, five-treatment, unbalanced crossover study in 24 healthy subjects. In a second study, the effects of steady-state dapagliflozin on the pharmacokinetics of 25 mg warfarin or 0.25 mg digoxin were assessed in an open-label, randomized, two-period, two-treatment crossover study in 30 healthy subjects divided into two cohorts. The potential pharmacodynamic interaction between dapagliflozin and warfarin was also evaluated. RESULTS: CONCLUSION:
|
Authors | Sreeneeranj Kasichayanula, Ming Chang, Xiaoni Liu, Wen-Chyi Shyu, Steven C Griffen, Frank P LaCreta, David W Boulton |
Journal | Advances in therapy
(Adv Ther)
Vol. 29
Issue 2
Pg. 163-77
(Feb 2012)
ISSN: 1865-8652 [Electronic] United States |
PMID | 22271159
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Arrhythmia Agents
- Anticholesteremic Agents
- Anticoagulants
- Antihypertensive Agents
- Benzhydryl Compounds
- Glucosides
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
- Tetrazoles
- dapagliflozin
- Warfarin
- Digoxin
- Valsartan
- Simvastatin
- Valine
|
Topics |
- Adult
- Anti-Arrhythmia Agents
(pharmacokinetics)
- Anticholesteremic Agents
(pharmacokinetics)
- Anticoagulants
(pharmacokinetics)
- Antihypertensive Agents
(pharmacokinetics)
- Benzhydryl Compounds
- Cross-Over Studies
- Diabetes Mellitus, Type 2
(drug therapy)
- Digoxin
(pharmacokinetics)
- Drug Interactions
- Female
- Glucosides
(pharmacokinetics)
- Humans
- Hypoglycemic Agents
(pharmacokinetics)
- Male
- Middle Aged
- Simvastatin
(pharmacokinetics)
- Sodium-Glucose Transporter 2 Inhibitors
- Tetrazoles
(pharmacokinetics)
- Valine
(analogs & derivatives, pharmacokinetics)
- Valsartan
- Warfarin
(pharmacokinetics)
|